{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:02:05Z","timestamp":1784649725674,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102884","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:23:17Z","timestamp":1782228197000},"page":"102884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling"],"prefix":"10.1016","volume":"7","author":[{"given":"Constanza","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyshka M.","family":"Reyes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsuk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reona","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Schmiechen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Sakhalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel G.","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie R.","family":"Nedrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayla","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E.","family":"Citrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy E.","family":"Escorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-2055","authenticated-orcid":false,"given":"Rosa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102884_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib4","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102884_bib5","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102884_bib6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib7","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10555-024-10214-6","article-title":"CAR T-cells for pediatric solid tumors: where to go from here?","volume":"43","author":"Trautmann","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.xcrm.2026.102884_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102884_bib11","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102884_bib12","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-17-2153","article-title":"Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8(+) T Cells","volume":"78","author":"Johnson","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102884_bib13","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102884_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2022.08.010","article-title":"A Primer on Radiopharmaceutical Therapy","volume":"115","author":"Salerno","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.xcrm.2026.102884_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study","volume":"24","author":"Matthay","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102884_bib17","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.21.00703","article-title":"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium","volume":"39","author":"DuBois","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102884_bib18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","article-title":"131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study","volume":"21","author":"Yanik","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.xcrm.2026.102884_bib19","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2002.08.124","article-title":"Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma","volume":"20","author":"Yanik","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102884_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29117","article-title":"A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study","volume":"68","author":"Weiss","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.xcrm.2026.102884_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.1990.tb06363.x","article-title":"Expression of integrins in human bone marrow","volume":"76","author":"Soligo","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2026.102884_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1535-7163.MCT-24-0370","article-title":"Evaluation of VLA-4 (integrin alpha4beta1) as a shared target for radiopharmaceutical therapy across solid tumors","volume":"24","author":"Reyes-Gonz\u00e1lez","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2026.102884_bib23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102884_bib24","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","article-title":"Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice","volume":"17","author":"Klebanoff","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102884_bib25","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib26","article-title":"Bottom up proteomics identifies neuronal differentiation pathway networks activated by cathepsin inhibition treatment in neuroblastoma cells that are enhanced by concurrent 13-cis retinoic acid treatment","volume":"232","author":"Halakos","year":"2021","journal-title":"J. Proteonomics"},{"key":"10.1016\/j.xcrm.2026.102884_bib27","doi-asserted-by":"crossref","first-page":"21588","DOI":"10.1074\/jbc.M110.193755","article-title":"Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells","volume":"286","author":"Veeraraghavan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102884_bib28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.vetimm.2011.11.018","article-title":"Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma","volume":"145","author":"Zwingenberger","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.xcrm.2026.102884_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034404","article-title":"In-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphoma","volume":"7","author":"Zwingenberger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102884_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/8532e291-73d3-461c-810d-0533ccb1eba0","article-title":"Very late antigen-4 (alpha(4)beta(1) Integrin) targeted PET imaging of multiple myeloma","volume":"8","author":"Soodgupta","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102884_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nucmedbio.2018.02.005","article-title":"Preliminary evaluation of (18)F-labeled LLP2A-trifluoroborate conjugates as VLA-4 (alpha(4)beta(1) integrin) specific radiotracers for PET imaging of melanoma","volume":"61","author":"Roxin","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.xcrm.2026.102884_bib32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1535-7163.MCT-07-0575","article-title":"In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against alpha4beta1 integrin","volume":"7","author":"Peng","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2026.102884_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.122.264349","article-title":"First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging","volume":"64","author":"Laforest","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41598-021-03748-0","article-title":"Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival","volume":"12","author":"Hathi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102884_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11307-021-01666-1","article-title":"PET Imaging of VLA-4 in a New BRAF(V600E) Mouse Model of Melanoma","volume":"24","author":"Bellavia","year":"2021","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.xcrm.2026.102884_bib36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.2967\/jnumed.114.144881","article-title":"PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates","volume":"55","author":"Beaino","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu4417","article-title":"Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma","volume":"11","author":"Sodji","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102884_bib38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-023-37825-x","article-title":"Expansion of circulating stem-like CD8(+) T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice","volume":"14","author":"Onyshchenko","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102884_bib39","first-page":"4053","article-title":"Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification","volume":"53","author":"Imamura","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102884_bib40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1078-0432.CCR-09-1865","article-title":"High Frequency of p53\/MDM2\/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma","volume":"16","author":"Carr-Wilkinson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102884_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006501","article-title":"Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome","volume":"12","author":"Padovan-Merhar","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.xcrm.2026.102884_bib42","first-page":"6597","article-title":"Direct Evidence for the Contribution of Activated N-ras and K-ras Oncogenes to Increased Intrinsic Radiation Resistance in Human Tumor Cell Lines1","volume":"60","author":"Bernhard","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102884_bib43","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.7150\/thno.42602","article-title":"Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation","volume":"10","author":"Le Grand","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2026.102884_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-025-00857-1","article-title":"Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments","volume":"9","author":"Jing","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.102884_bib45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2026.102884_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0353","article-title":"Immune responses to gut bacteria associated with time to diagnosis and clinical response to T cell-directed therapy for type 1 diabetes prevention","volume":"15","author":"Xie","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102884_bib47","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.xcrm.2026.102884_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100942","article-title":"Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models","volume":"2","author":"Li","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.xcrm.2026.102884_bib49","doi-asserted-by":"crossref","first-page":"O8","DOI":"10.1186\/2051-1426-3-S2-O8","article-title":"Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3","volume":"3","author":"Powderly","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102884_bib50","doi-asserted-by":"crossref","first-page":"e005881","DOI":"10.1136\/jitc-2022-005881","article-title":"Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma","volume":"11","author":"Sun","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102884_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102884_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102884_bib53","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102884_bib54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2026.102884_bib55","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive Integration of Single-Cell Data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102884_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giaa151","article-title":"SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data","volume":"9","author":"Young","year":"2020","journal-title":"GigaScience"},{"key":"10.1016\/j.xcrm.2026.102884_bib57","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102884_bib58","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat. Protoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:02:49Z","timestamp":1784646169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126003010"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102884","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102884"}}